Emparol 25 mg (Tablet)
Unit Price: ৳ 40.00 (1 x 14: ৳ 560.00)
Strip Price: ৳ 560.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Drug international ltd |
| Also available as |
Title
- Emparol 25 mg Tablet
Categories
- Medicine
- Diabetes
- Cardiovascular Health
Description
- Emparol is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Dosage and administration
- Recommended dose: 10 mg once daily, taken in the morning, with or without food. Dose may be increased to 25 mg once daily in patients tolerating Emparol. Correcting volume depletion is recommended in patients with volume depletion prior to initiation of Empagliflozin.
Interaction
- Diuretics: Co-administration results in increased urine volume.
- Insulin or Insulin Secretagogues: Co-administration increases the risk for hypoglycemia.
- Positive Urine Glucose Test: Monitoring with urine glucose tests is not recommended.
- Interference with 1,5-anhydroglucitol (1,5-AG) Assay: Monitoring with 1,5-AG assay is not recommended.
Contraindications
- Empagliflozin is contraindicated in patients with history of serious hypersensitivity reaction to Empagliflozin or any of its ingredients, severe renal impairment, end-stage renal disease, or dialysis.
Side effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy and lactation
- Empagliflozin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not recommended when breastfeeding.
Precautions and warnings
- Assessment of renal function is recommended prior to initiation of Emparol and periodically thereafter. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m².
Overdose effects
- Supportive measures should be employed in the event of an overdose with Emparol. Removal of Emparol by hemodialysis has not been studied.
Therapeutic class
- SGLT2 Inhibitors
Storage conditions
- Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.
Chemical structure
- Molecular Formula: C23H27ClO7
Commonly asked questions
- Emparol 25 mg Tablet is a SGLT-2 inhibitor which reduces the reabsorption of glucose from the kidney.
- It is commonly used to improve glycemic control in adults.
- May be unsafe to use during pregnancy.
- Probably unsafe to use during breastfeeding.
- Should be used cautiously in patients with underlying kidney disease.
- No dose adjustment is needed for patients with mild to moderate liver disease.
Additional attributes
- Reduces renal absorption of glucose
- Increases glucose excretion
- Assists weight loss
- Reduces blood pressure
- Affects glycemic control
- May cause positive urine glucose tests
- May interfere with 1,5-AG assay
- Reduces risk of cardiovascular death
- Improves glycaemic control
- Increases urine volume
- Causes hypoglycemia risk
- Can lead to dehydration
- Affects blood pressure
- Leads to increased thirst
- Can result in urinary tract infections
- May cause genital mycotic infections
- Needs renal function assessment
- Should not be used in severe renal impairment
- Should not be used in end-stage renal disease
- May not be excreted in human milk
- Needs careful consideration during pregnancy
- Not recommended for breastfeeding
- Has volume depletion correction recommendation
- Has no eGFR adjustment in certain patients
- Supportive measures needed in overdose
- No specific hemodialysis removal study
- Belongs to SGLT2 inhibitors therapeutic class
- Stored below 30°C
- Protected from light and moisture
- Assessment of renal function
- No eGFR adjustment
- Molecular Formula C23H27ClO7